详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China [2]Department of Pediatrics, West China Second University Hospital, Sichuan University, No. 20, 3rd section, South Renmin Road, Chengdu 610041, China [3]Department of Urologic Surgery, University of California Davis, Davis, CA, USA

出处：

DOI：

ISSN：

关键词： Prostate cancer Immunotherapy Adoptive cell therapy Immune checkpoint inhibitors Vaccine

摘要：

In recent years, cancer immunotherapy has received widespread attention due to significant tumor clearance in some malignancies. Various immunotherapy approaches, including vaccines, immune checkpoint inhibitors, oncolytic virotherapy, bispecific T cell engagers, and adoptive T cell transfer, have completed or are undergoing clinical trials for prostate cancer. Despite immune checkpoint blockade's extraordinary effectiveness in treating a variety of cancers, targeted prostate cancer treatment using the immune system is still in its infancy. Multiple factors including the heterogeneity of prostate cancer, the cold tumor microenvironment, and a low level of neoantigens, contribute to the poor immunotherapy response. Significant effort is being devoted to improving immune-based prostate cancer therapy. Recently, several key discoveries demonstrate that prostate cancer immunotherapy agents may be used to promise better prognosis for patients as part of combination strategies with other agents targeting tumor-associated immune mechanism of resistance. Here, this review comprehensively examines the recent advancements in immunotherapy for prostate cancer, exploring its potential synergistic effects when combined with other treatment modalities to enhance clinical efficacy.Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版

：

大类 | 2 区

医学

小类 | 2 区血液学 2 区肿瘤学

第一作者：

第一作者机构： [1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models [2]Development of immunotherapy for brain metastasis (Review). [3]BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma [4]Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma. [5]Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials. [6]Immunotherapy vs. Chemotherapy in Subsequent Treatment of Malignant Pleural Mesothelioma: Which Is Better? [7]Evolving perspectives regarding the role of the PD-1/PD-L1 pathway in gastric cancer immunotherapy [8]Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits [9]Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy. [10]The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.